RET T930P

CI-VAR-00004354Explore in graph →CIViC 4780

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm2
RET T930P	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID11863 To assess recurrent somatic mutations in the RET kinase domain (T930K/M/P and D898_E901del) that were identified in a large study of 37,056 Chinese cancer patients, in vitro functional tests were run … (full text at CIViC) PMID 32284345 · Zhao et al., 2020 · Open in CIViC	civic
RET T930P	Pralsetinib + SelpercatinibSubstitutes	Predictive	D	Supports Sensitivity Response	3	submitted	EID11868 Ba/F3 transformed cells harboring RET D898_E901del, T930K, T930P, or M918T mutations were shown to be sensitive to the highly selective RET inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667… (full text at CIViC) PMID 32284345 · Zhao et al., 2020 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.